Active Ingredient History
Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE). Lisinopril is marketed under the brand name ZESTRIL. ZESTRIL is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. It is also indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decreased aldosterone secretion. While the mechanism through which ZESTRIL lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, ZESTRIL is antihypertensive even in patients with low-renin hypertension. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 2)
Aging (Phase 2)
Albuminuria (Phase 2)
Aortic Stenosis, Subvalvular (Phase 3)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Cardiomyopathies (Phase 4)
Cardiotoxicity (Phase 2)
Cardiovascular Diseases (Phase 4)
Cognitive Dysfunction (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 3)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 4)
Drug-Related Side Effects and Adverse Reactions (Early Phase 1)
Drugs, Generic (Phase 1)
Essential Hypertension (Phase 4)
Fasting (Phase 1)
Gastroparesis (Phase 1)
Genetic Predisposition to Disease (Phase 2)
Glomerulonephritis (Phase 2)
Glomerulosclerosis, Focal Segmental (Phase 2)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Failure, Systolic (Phase 4)
HIV (Phase 4)
HIV Infections (Phase 2)
Hypercholesterolemia (Phase 3)
Hyperkalemia (Phase 3)
Hyperlipidemias (Phase 2)
Hyperoxaluria (Phase 3)
Hypertension (Phase 4)
Hypertrophy, Left Ventricular (Phase 3)
Hypotension (Phase 4)
Kidney Diseases (Phase 3)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma (Phase 2)
Metabolic Syndrome (Phase 1/Phase 2)
Muscular Dystrophies, Limb-Girdle (Phase 2/Phase 3)
Muscular Dystrophy, Duchenne (Phase 2/Phase 3)
Myocardial Infarction (Phase 3)
Myocardial Ischemia (Phase 3)
Neoplasms (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 2)
Obesity, Abdominal (Phase 3)
Oligospermia (Phase 2)
Osteoarthritis (Phase 4)
Osteonecrosis (Phase 2)
Pneumonia (Phase 4)
Polycystic Kidney Diseases (Phase 3)
Prehypertension (Phase 1/Phase 2)
Prostatic Neoplasms (Early Phase 1)
Proteinuria (Phase 4)
Renal Dialysis (Phase 3)
Renal Insufficiency, Chronic (Phase 4)
Sarcoma (Phase 2)
Stroke (Phase 4)
Therapeutic Equivalency (Phase 1)
Urogenital Diseases (Early Phase 1)
Urological Manifestations (Phase 4)
Ventricular Dysfunction, Left (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
